Financial Analysis: Endonovo Therapeutics (OTCMKTS:ENDVD) vs. Regulus Therapeutics (NASDAQ:RGLS)

Regulus Therapeutics (NASDAQ:RGLS) and Endonovo Therapeutics (OTCMKTS:ENDVD) are both small-cap medical companies, but which is the better investment? We will compare the two businesses based on the strength of their valuation, risk, analyst recommendations, profitability, institutional ownership, dividends and earnings.

Analyst Recommendations

This is a summary of current ratings for Regulus Therapeutics and Endonovo Therapeutics, as reported by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Regulus Therapeutics	0	1	5	0	2.83
Endonovo Therapeutics	0	0	0	0	0.00

Regulus Therapeutics presently has a consensus target price of $10.80, suggesting a potential upside of 570.81%. Given Regulus Therapeutics’ stronger consensus rating and higher possible upside, analysts clearly believe Regulus Therapeutics is more favorable than Endonovo Therapeutics.

Institutional and Insider Ownership

92.4% of Regulus Therapeutics shares are owned by institutional investors. 4.4% of Regulus Therapeutics shares are owned by company insiders. Comparatively, 5.6% of Endonovo Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.

Valuation & Earnings

This table compares Regulus Therapeutics and Endonovo Therapeutics”s top-line revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Regulus Therapeutics	N/A	N/A	-$30.04 million	($1.07)	-1.50
Endonovo Therapeutics	$170,000.00	0.01	-$400,000.00	N/A	N/A

Endonovo Therapeutics has higher revenue and earnings than Regulus Therapeutics.

Volatility and Risk

Regulus Therapeutics has a beta of 1.61, meaning that its share price is 61% more volatile than the S&P 500. Comparatively, Endonovo Therapeutics has a beta of 1.98, meaning that its share price is 98% more volatile than the S&P 500.

Profitability

This table compares Regulus Therapeutics and Endonovo Therapeutics’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Regulus Therapeutics	N/A	-53.07%	-48.58%
Endonovo Therapeutics	-6,075.54%	N/A	-279.35%

Summary

Regulus Therapeutics beats Endonovo Therapeutics on 6 of the 11 factors compared between the two stocks.

About Regulus Therapeutics

Regulus Therapeutics Inc., a clinical-stage biopharmaceutical company, focuses on discovery and development of drugs that targets microRNAs to treat a range of diseases in the United States. Its product candidates include RGLS8429, an anti-miR next generation oligonucleotide targeting miR-17, which is in Phase 1b clinical trial for the treatment of autosomal dominant polycystic kidney disease. The company is also developing a pipeline of preclinical drug products for target organ-selective delivery strategies. Regulus Therapeutics Inc. was incorporated in 2007 and is headquartered in San Diego, California.

About Endonovo Therapeutics

Endonovo Therapeutics, Inc. is a biotechnology company, which engages in the development of bio-electronic approach to regenerative medicine. The firm also develops, manufactures and distributes evolutionary medical devices focused on the healing of wounds and reduction of pain, edema and inflammation on and in the human body. Its technology and products include Electroceuticals, EFECT Trial, SofPulse, Electroceutical Therapy, and Scientific Studies. The company was founded in November 2008 and is headquartered in Woodland Hills, CA.